07:02 EDT Regulus (RGLS) to be acquired by Novartis (NVS) for $7.00 per share in cash
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS:
- Promising Phase 1b Results and Favorable Safety Profile Position Regulus’s Farabursen as a Strong Investment in ADPKD Treatment
- Promising Phase 1b Results and Future Prospects Drive Buy Rating for Regulus’s Farabursen
- Wells upgrades Regulus to Overweight after farabursen data reported
- Regulus upgraded to Overweight from Equal Weight at Wells Fargo
- Regulus Announces Positive Phase 1b Study Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue